A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB).
Expert Rev Vaccines
; 22(1): 530-544, 2023.
Article
em En
| MEDLINE
| ID: mdl-37278390
The four-component serogroup B meningococcal vaccine 4CMenB (Bexsero®, GSK) was licensed in 2013 and has acquired substantial safety evidence through clinical trial and real-world data. Availability of real-world and clinical 4CMenB safety evidence is important to help address vaccination hesitancy. This comprehensive review of safety data, from 9 years of 4CMenB use including recent data from the real world, shows no significant safety issues in a variety of age groups. Data show that transient fever may occur after vaccination. Invasive meningococcal disease, although rare, can be life-threatening. Abundant safety data from this review can help reassure individuals and healthcare providers on the use of 4CMenB.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas Meningocócicas
/
Neisseria meningitidis Sorogrupo B
/
Infecções Meningocócicas
/
Neisseria meningitidis
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Child
/
Humans
/
Infant
Idioma:
En
Revista:
Expert Rev Vaccines
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos